Vol. 2 No. 5 (2022): May
Reimbursement Recommendations

Alpha1-Proteinase Inhibitor (Human) (Zemaira)

  • CADTH
PDF HTML
DOI: https://doi.org/10.51731/cjht.2022.323

Published May 2, 2022

Key Messages

  • CADTH recommends that Zemaira be reimbursed for the treatment of severe alpha1-proteinase inhibitor (A1-PI) deficiency if certain conditions are met.
  • Zemaira should only be covered to treat patients with severe A1-PI deficiency (e.g., genotypes PiZZ, PiZ(null), Pi(null,null), PiSZ) and clinical evidence of emphysema who are nonsmokers for at least 6 months.
  • Zemaira should only be reimbursed if prescribed by a respirologist and the cost of Zemaira is reduced.
PDF HTML